肝腎綜合症市場 - 全球及區域分析：按區域 - 分析與預測（2025-2035）

全球肝腎綜合症市場 - 分析與預測（2025-2035）

肝腎症候群（HRS）是晚期肝病的一種嚴重且常常危及生命的併發症，尤其是在肝硬化或嚴重肝功能衰竭患者中。

肝腎症候群的特徵是進行性性腎功能障礙，其原因並非腎臟本身疾病，而是由肝功能衰竭引起的嚴重血流動力學改變。在肝腎症候群中，肝功能下降會導致顯著的血流動力學改變。臨床上將肝腎症候群分為兩型：1 型（現稱為 HRS-AKI）進展迅速，如果不進行干預，預後很差，而 2 型（現稱為 HRS-CKD）病程較為緩慢。如果不及時治療，這種疾病的死亡率很高，而肝臟移植是最終的治療方法。藥物治療，例如血管收縮劑（例如terlipressin）與白蛋白聯合使用，目的是改善腎臟血流，為移植或康復提供橋樑。

肝腎綜合症市場的主要促進因素之一是肝病（尤其是肝硬化）盛行率的不斷上升。酒精性肝病、非酒精性脂肪肝病（NAFLD）和病毒性肝炎等慢性肝病在全球呈現上升趨勢，主要原因是不良生活習慣、不健康的飲食習慣以及飲酒量增加。隨著全球人口老化，慢性肝功能衰竭的發生率預計會增加，導致患有進行進行性肝功能衰竭和肝腎症候群等併發症風險的人數增加。肝硬化是肝腎症候群的主要原因，其病情通常會發展到腎功能障礙成為嚴重問題，需要專門治療。肝病盛行率的上升推動了對能夠預防或控制肝腎症候群的治療性介入的需求。

儘管肝腎綜合症市場前景光明，但市場仍面臨諸多挑戰。其中一大障礙是高昂的治療和肝臟移植費用。諸如特利加壓素等血管收縮劑和白蛋白療法通常需要長期用藥，這給患者和醫療保健系統帶來了巨大的成本負擔。此外，雖然肝臟移植通常是晚期肝腎症候群患者的最終治療方法，但由於捐贈器官供應不足，肝臟移植仍然是一項昂貴且複雜的治療方法。捐贈器官的短缺限制了符合移植條件的患者數量，而與移植相關的費用也給患者和醫療保健系統帶來了沉重的經濟負擔，尤其是在發展中地區。這些經濟限制阻礙了最佳治療方案的廣泛應用，限制了市場成長。此外，儘管治療方法方法取得了進展，但目前肝腎症候群的治療方案仍然有限，主要包括血管收縮劑和白蛋白輸注，通常與肝臟移植相結合。這種狹窄的治療窗口令醫護人員和患者都感到沮喪，尤其是因為這些療法本身並不能治癒疾病。

全球肝腎綜合症市場競爭激烈，多家主要企業推動創新和市場成長。包括 Mallinckrodt Pharmaceuticals、Noorik Biopharmaceuticals、BioVie Inc. 和 Ferring Pharmaceuticals 在內的主要企業處於市場前沿，各自透過創新治療方法和治療方法做出貢獻。這些公司採取各種策略方針，致力於創新、策略夥伴關係和市場滲透。製藥公司增加對研發的投資，以創造更有效、更有針對性的肝腎症候群治療方法，例如可以改善腎灌注並解決肝腎症候群根本原因的新型血管收縮劑和抗發炎藥物。此外，該公司與 FDA 和 EMA 等監管機構密切合作，以加速其產品進入市場並利用監管部門的核准來擴大其市場範圍。

肝腎綜合症市場細分

細分1：依地區

• 北美洲
• 歐洲
• 亞太地區

新興市場中肝病和肝硬化綜合症（HRS）的發生率不斷上升，而專科醫療服務相對有限，這為企業提供了巨大的機會。亞太、拉丁美洲和非洲地區的肝病發生率高，且存在諸如缺乏先進治療手段等醫療保健挑戰，這些都為企業帶來了巨大的市場機會。能夠根據這些地區的經濟現狀（例如經濟承受能力以及與當地醫療機構合作）調整經營模式的企業，將能夠獲得顯著的市場佔有率。

目錄

執行摘要

第1章 全球肝腎綜合症市場：產業分析

• 市場概況與生態系統
• 流行病學分析
• 主要市場趨勢
  • 影響分析
• 監管狀況
• 管道分析
• 市場動態
  • 概述
  • 市場促進因素
  • 市場限制
  • 市場機會

第2章 全球肝腎綜合症市場（依地區）價值，2023-2035

• 北美洲
  • 市場動態
  • 市場規模及預測
  • 北美肝腎綜合症市場（依國家/地區，百萬美元），2023-2035年
• 歐洲
  • 市場動態
  • 市場規模及預測
  • 歐洲肝腎綜合症市場（依國家/地區，百萬美元），2023-2035年
• 亞太地區
  • 市場動態
  • 市場規模及預測
  • 亞太地區肝腎症候群市場（依國家/地區，百萬美元），2023-2035年

第3章 競爭格局與公司概況

• 競爭格局
• 公司簡介
  • Mallinckrodt Pharmaceuticals.
  • Noorik Biopharmaceuticals.
  • Ocelot Bio.
  • BioVie Inc.
  • Ferring Pharmaceuticals.
  • 其他

第4章 調查方法

Global Hepatorenal Syndrome Market, Analysis and Forecast: 2025-2035

Hepatorenal syndrome (HRS) is a serious and often life-threatening complication of advanced liver disease, particularly in patients with cirrhosis and severe liver failure. It is characterized by progressive kidney dysfunction that arises not from intrinsic kidney disease but as a result of severe circulatory changes triggered by liver failure. In hepatorenal syndrome, reduced liver function leads to profound alterations in blood flow dynamics. Clinically, hepatorenal syndrome is divided into two types: Type 1 (now called HRS-AKI), which progresses rapidly and is associated with very poor prognosis without intervention, and Type 2 (now called HRS-CKD), which has a slower, more gradual course. The condition is strongly associated with high mortality rates if not promptly treated, with liver transplantation being the definitive therapy. Pharmacologic treatments, such as vasoconstrictors (e.g., terlipressin) combined with albumin, aim to improve renal blood flow and serve as a bridge to transplantation or recovery.

One of the key drivers of the hepatorenal syndrome market is the increasing prevalence of liver diseases, particularly cirrhosis. Chronic liver conditions, such as alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and viral hepatitis, are rising globally, largely due to lifestyle factors, unhealthy diets, and increasing alcohol consumption. As the global population ages, the incidence of chronic liver failure is also expected to grow, which in turn increases the number of individuals at risk of developing advanced liver failure and its complications, such as hepatorenal syndrome. Cirrhosis, the leading cause of hepatorenal syndrome, often progresses to a point where kidney dysfunction is a critical concern, prompting the need for specialized treatments. The rise in liver disease prevalence has amplified the demand for therapeutic interventions that can prevent or manage hepatorenal syndrome.

Despite the promising opportunities, several challenges remain in the hepatorenal syndrome market. A significant barrier is the high cost of treatment and liver transplantation. Treatments such as vasoconstrictors, such as terlipressin, and albumin therapy require long-term administration in many cases, which can lead to substantial costs for patients and healthcare systems. Additionally, liver transplantation is often the most definitive treatment for patients with advanced hepatorenal syndrome, but it remains a costly and complex procedure, with significant barriers in terms of the availability of donor organs. The shortage of donor organs limits the number of patients who can receive a transplant, and the costs associated with the procedure place a significant financial burden on patients and healthcare systems, particularly in developing regions. These financial constraints can prevent the wide-scale adoption of the best treatment options, limiting market growth. Adding to this, despite advancements, current treatment options for hepatorenal syndrome remain limited, primarily revolving around vasoconstrictors and albumin infusions, which are often used in conjunction with liver transplantation. This narrow therapeutic window can be frustrating for both healthcare providers and patients, especially as these treatments are not curative on their own.

The global hepatorenal syndrome market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Mallinckrodt Pharmaceuticals, Noorik Biopharmaceuticals, BioVie Inc., and Ferring Pharmaceuticals are at the forefront of the market, each contributing through innovative therapies and treatments. These companies are adopting a variety of strategic approaches, focusing on innovation, strategic partnerships, and market penetration. Pharmaceutical companies are increasingly investing in research and development to create more effective and targeted treatments for hepatorenal syndrome, such as novel vasoconstrictors and anti-inflammatory agents that can improve renal perfusion and address the underlying causes of hepatorenal syndrome. In addition, companies are leveraging regulatory approvals to broaden market access, particularly by working closely with agencies such as the FDA and EMA to gain faster market entry for their products.

Hepatorenal Syndrome Market Segmentation:

Segmentation 1: by Region

• North America
• Europe
• Asia-Pacific

There is a growing opportunity for companies to expand into emerging markets, where the prevalence of liver disease and HRS is rising but access to specialized treatments is limited. Asia-Pacific, Latin America, and Africa are regions where both the incidence of liver diseases and healthcare challenges such as a lack of access to advanced treatments create a significant market opportunity. Companies that can adapt their business models to meet the economic realities of these regions, such as offering affordable pricing or collaborating with local healthcare providers, stand to gain a substantial share of the market.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Hepatorenal Syndrome Market: Industry Analysis

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis
• 1.3 Key Market Trends
  • 1.3.1 Impact Analysis
• 1.4 Regulatory Landscape
• 1.5 Pipeline Analysis
• 1.6 Market Dynamics
  • 1.6.1 Overview
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Hepatorenal Syndrome Market (Region), Value ($Million), 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
  • 2.1.3 North America Hepatorenal Syndrome Market, by Country ($Million), 2023-2035
    • 2.1.3.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
  • 2.2.3 Europe Hepatorenal Syndrome Market, by Country ($Million), 2023-2035
    • 2.2.3.1 U.K.
    • 2.2.3.2 France
    • 2.2.3.3 Germany
    • 2.2.3.4 Italy
    • 2.2.3.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
  • 2.3.3 Asia-Pacific Hepatorenal Syndrome Market, by Country ($Million), 2023-2035
    • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Partnership, Alliances and Business Expansion
  • 3.1.3 New Offerings
  • 3.1.4 Regulatory Activities
  • 3.1.5 Funding Activities
• 3.2 Company Profiles
  • 3.2.1 Mallinckrodt Pharmaceuticals.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Noorik Biopharmaceuticals.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Ocelot Bio.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 BioVie Inc.
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Ferring Pharmaceuticals.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Top Competitors
    • 3.2.5.4 Target Customers/End-Users
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 Others

4. Research Methodology

List of Figures

• Figure: Global Hepatorenal Syndrome Market Coverage
• Figure: Global Hepatorenal Syndrome Market Key Trends, Impact Analysis, 2023-2035

List of Tables

• Table: Global Hepatorenal Syndrome Market Dynamics, Impact Analysis
• Table: Global Hepatorenal Syndrome Market (by Region), $Million, 2023-2035